Evidence map›Paper›PMID 32622138›Full record

ArticleJournal of the American Academy of Dermatology2020

Evaluating the effect of prior authorizations in patients with complex dermatologic conditions.

Olivia S Jew, Joyce Okawa, John S Barbieri, Joanne McCaffrey, Elizabeth Hayward, Victoria P Werth

Abstract read
In one paragraph

Article in Journal of the American Academy of Dermatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Impact of a Standardized, Pharmacist-Initiated "Test-Claim" Workflow for Anticipating Barriers to Accessing Discharge Antimicrobials.The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2023
    Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Olivia S JewPerelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; The Wharton School, University of Pennsylvania, Philadelphia, Pennsylvania; Dermatology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
Joyce OkawaDermatology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
John S BarbieriDermatology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
Joanne McCaffreyDermatology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
Elizabeth HaywardDermatology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
Victoria P WerthDermatology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania; Dermatology, CMC VA Medical Center, Philadelphia, Pennsylvania. Electronic address: werth@pennmedicine.upenn.edu.

Funding

Penn Dermatology Research Training ProgramT32AR007465 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI Elizabeth Anne Grice, David Joel Margolis · 1986 to 2026
$9.0M
Optimization of Clinical Trial Design in Cutaneous LupusR01AR071653 · NIAMS · UT SOUTHWESTERN MEDICAL CENTER · PI CHONG, BENJAMIN FRANKLIN, WERTH, VICTORIA P · 2018 to 2020
$653k
NIAMS NIH HHS R01 AR071653NIAMS NIH HHS T32 AR007465
6 · The paper itself

Abstract

backgroundIn dermatology, prior authorizations can delay treatment, decrease patient adherence, and deter providers from advocating for their patients. Patients with complex dermatologic conditions, often requiring off-label treatments, may face particularly significant insurance barriers.

objectiveEvaluate the effect of prior authorizations in patients with complex dermatologic conditions.

methodsThis prospective cohort study assessed patients treated by a dermatologist during 5 months who specialized in complex dermatology. Patients included were older than 18 years, treated at V.P.W.'s rheumatology-dermatology clinic, and prescribed a medication or ordered a diagnostic procedure that elicited an insurance prior authorization. Data on prior authorization outcome, administrative time, and delay to treatment were collected.

resultsOf 51 prior authorizations, 51% were initially denied, with systemic medications more likely denied than topical ones (P < .001). Total administrative time spent on 50 prior authorizations tracked was 62.5 hours (median time per prior authorization 30 minutes [interquartile range 17-105 minutes]). Time to access treatment was tracked for 80% of prior authorizations; median delay was 12 days [interquartile range 5.5-23 days]. LIMITATIONS: Single-center, single-provider patient panel.

conclusionPatients with complex dermatologic conditions face a significant barrier to care because of prior authorizations. The administrative burden for provider practices to address these prior authorizations is substantial and may warrant a streamlined system in collaboration with insurers.

Indexed as

AdultAgedAged, 80 and overCost of IllnessDermatologyDrug PrescriptionsFemaleHealth Services AccessibilityHumansMaleMiddle AgedPrior AuthorizationProspective StudiesRheumatologySkin DiseasesTime Factorscomplex medical dermatologyhealth care deliveryprior authorizations

Identifiers

PMID32622138
PMCPMC7936393

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.